Sirolimus-coated balloon versus everolimus-eluting stent in de novo coronary artery disease: Rationale and design of the TRANSFORM II randomized clinical trial.
Antonio GrecoAlessandro SciahbasiAlexandre AbizaidRoxana MehranStefano RigattieriJose M de la Torre HernandezFernando AlfonsoBernardo CortesePublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2022)
The randomized TRANSFORM II trial will determine whether a novel SCB is noninferior to a current everolimus-eluting stent when adopted for the treatment of de novo lesions in coronary vessels with a diameter between 2 and 3 mm.
Keyphrases
- coronary artery disease
- phase iii
- double blind
- phase ii
- clinical trial
- open label
- percutaneous coronary intervention
- coronary artery
- study protocol
- placebo controlled
- cardiovascular events
- coronary artery bypass grafting
- type diabetes
- randomized controlled trial
- cardiovascular disease
- combination therapy
- left ventricular